NICE terminates yet another appraisal of daratumumab

22 September 2021 - This is the third terminated appraisal of daratumumab. ...

Read more →

NHS patients gain access to COVID-19 treatment Ronapreve

21 September 2021 - The UK has secured supply of Ronapreve, a new COVID-19 therapeutic developed by Regeneron and Roche ...

Read more →

Keytruda made available on the NHS for certain oesophageal cancer patients

17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...

Read more →

BioCryst’s HAE med Orladeyo wins NICE nod

16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...

Read more →

NICE backs Opdivo for head and neck cancer

15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...

Read more →

NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug

10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...

Read more →

Professor Gillian Leng to retire from NICE

9 September 2021 - Professor Leng has spent more than 20 years working at NICE. ...

Read more →

NICE recommends treatment for people with juvenile idiopathic arthritis

9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...

Read more →

Nivolumab scores a rare 'no' from NICE

8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...

Read more →

NICE draft guidance recommends apalutamide for treating prostate cancer

8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...

Read more →

NICE recommends Novartis’ Cosentyx for children with severe psoriasis

3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...

Read more →

NICE approves ground-breaking cholesterol lowering drug inclisiran

1 September 2021 - NICE has today issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by ...

Read more →

World first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio (inclisiran)

1 September 2021 - Agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management ...

Read more →

NICE ‘no’ for Janssen’s Darzalex combo

27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, ...

Read more →

NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer

25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or ...

Read more →